N

Nichi-Iko Pharmaceutical Co Ltd
TSE:4541

Watchlist Manager
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Watchlist
Price: 0.0001 JPY Market Closed
Market Cap: 776 550.9T JPY
Have any thoughts about
Nichi-Iko Pharmaceutical Co Ltd?
Write Note

Nichi-Iko Pharmaceutical Co Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nichi-Iko Pharmaceutical Co Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Change in Working Capital
-ÂĄ12.1B
CAGR 3-Years
N/A
CAGR 5-Years
8%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Change in Working Capital
-ÂĄ346.6B
CAGR 3-Years
N/A
CAGR 5-Years
-28%
CAGR 10-Years
-15%
Daiichi Sankyo Co Ltd
TSE:4568
Change in Working Capital
ÂĄ217.2B
CAGR 3-Years
N/A
CAGR 5-Years
62%
CAGR 10-Years
26%
Otsuka Holdings Co Ltd
TSE:4578
Change in Working Capital
-ÂĄ128.2B
CAGR 3-Years
-77%
CAGR 5-Years
-80%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Change in Working Capital
-ÂĄ48.6B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Astellas Pharma Inc
TSE:4503
Change in Working Capital
-ÂĄ129.6B
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
-11%
No Stocks Found

Nichi-Iko Pharmaceutical Co Ltd
Glance View

Market Cap
776 550.9T JPY
Industry
Pharmaceuticals

Nichi-Iko Pharmaceutical Co., Ltd., founded in Toyama, Japan, weaves its narrative around the essential fabric of healthcare by pioneering affordable and accessible medication. As a distinguished player in the generic pharmaceutical industry, Nichi-Iko specializes in the development, manufacture, and sale of a broad spectrum of generic drugs. Driven by the mission to enhance quality of life, the company meticulously focuses on producing high-quality, cost-effective alternatives to branded medications, thereby easing the financial burden on healthcare systems and patients alike. Its portfolio spans various therapeutic areas, strengthening its presence in both domestic and international markets. By investing strategically in R&D and leveraging advanced production techniques, Nichi-Iko ensures that its offerings meet rigorous standards, reinforcing trust and reliability in its brand. Financially, Nichi-Iko's revenue stream primarily hinges on the consistent demand for generics, amplified by the growing global emphasis on reducing healthcare costs. Licensing agreements and partnerships further bolster its financial framework, allowing the company to expand its product range and reach. The business model thrives on optimizing supply chain efficiencies and achieving economies of scale, translating into competitive pricing. Nichi-Iko’s commitment to innovation is not confined to generics; it is also venturing into biosimilars, tapping into a burgeoning market with expansive growth potential. By aligning its strategic direction with emerging healthcare trends and regulatory landscapes, Nichi-Iko positions itself as a resilient entity capable of sustaining its growth trajectory in a dynamic pharmaceutical sector.

Intrinsic Value
Not Available
N

See Also

What is Nichi-Iko Pharmaceutical Co Ltd's Change in Working Capital?
Change in Working Capital
-12.1B JPY

Based on the financial report for Mar 31, 2022, Nichi-Iko Pharmaceutical Co Ltd's Change in Working Capital amounts to -12.1B JPY.

What is Nichi-Iko Pharmaceutical Co Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
8%

Over the last year, the Change in Working Capital growth was -444%.

Back to Top